MedTrace Logo

A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma

NCT01890161 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2016-02-05

No results posted yet for this study

Summary

This is the first study in human patients with asthma that the sponsor is conducting in order to evaluate if there are signals that the investigational medication, AXP1275, may be a safe and effective treatment for asthma. The results of this study may help the sponsor to design additional studies.

Conditions

  • Atopic Asthma

Interventions

DRUG

AXP1275

AXP1275 50 mg (2 × 25-mg capsules)

DRUG

AXP1275 matching placebo

AXP1275 matching placebo (2 capsules)

Sponsors & Collaborators

  • Axikin Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Paul O'Byrne, MD · McMaster University

  • Louis-Philippe Boulet, MD · IUCPQ, Institut de cardiologie et de pneumologie de l'Hôpital Laval

  • Mark Fitzgerald, MD · University of British Columbia, Vancouver General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01890161 on ClinicalTrials.gov